TREM1 and cancer: Recently, a phase I clinical trial has been run to evaluate the safety, tolerability, and pharmacokinetics of the synthetic peptide nangibotide (LR12), the first drug candidate targeting TREM-1 to reach clinical stage development [239], and future assessment of this agent for cancer therapy is expected.